Hematology TimesNew cancer diagnosis linked to arterial thromboembolismAugust 15, 2017Lymphoma & Plasma Cell DisordersThrombosisNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesAnalysis reveals poor outcomes in refractory DLBCLAugust 12, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Oncology PracticeSolid organ transplantation contributes significantly to incidence of NHL among children and adolescentsAugust 3, 2017Lymphoma & Plasma Cell DisordersPediatricsPatient & Survivor CareTransplantAggressive Lymphomas
Hematology TimesFDA grants acalabrutinib breakthrough designationAugust 2, 2017Lymphoma & Plasma Cell DisordersPharmacyNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesDeveloping better mouse modelsJuly 28, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesHealth Canada approves new use for brentuximab vedotinJuly 26, 2017Lymphoma & Plasma Cell DisordersPharmacyHodgkin LymphomaAggressive Lymphomas
Hematology TimesHigh ORR with sequential regimen in CLLJuly 25, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCHMP recommends new indication for obinutuzumabJuly 22, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
Hematology TimesModified, CB-derived NK cells target CLL and BLJuly 21, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology NewsPembrolizumab takes on r/r PMBCLJuly 20, 2017Aggressive LymphomasLymphoma & Plasma Cell DisordersImmuno-oncology
Hematology NewsIMiD/Anti-CD20 combo induces complete responses in r/r NHLJuly 19, 2017Mantle Cell LymphomaLymphoma & Plasma Cell DisordersAggressive LymphomasImmuno-oncologyFollicular Lymphoma
Hematology TimesCAR T-cell therapy ‘highly effective’ in high-risk CLLJuly 19, 2017Leukemia, Myelodysplasia, TransplantationLymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology TimesPD-1 inhibitors treat resistant gray zone lymphomaJuly 15, 2017Lymphoma & Plasma Cell DisordersAggressive Lymphomas
Hematology TimesCTL019 produces responses in rel/ref DLBCLJuly 14, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive Lymphomas
Hematology TimesCombo demonstrates activity in CLL/SLL and FLJuly 11, 2017Lymphoma & Plasma Cell DisordersNon-Hodgkin LymphomaAggressive LymphomasFollicular Lymphoma
